Transplantation of endothelial progenitor cells in treating rats with IgA nephropathy

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Guo, Wei ^a,b   Feng, Jiang Min ^b   Yao, Li ^b   Sun, Li ^b   Zhu, Guang Qing ^a  

^a Fourth People's Hospital of Shenyang   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Endothelial progenitor cells; IgA nephropathy; Peritubular capillary; Transplantation

Indexed keywords

ANIMAL; BONE MARROW TRANSPLANTATION; CELL CULTURE; ENDOTHELIAL PROGENITOR CELL; FEMALE; GLOMERULONEPHRITIS, IGA; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RAT; SPRAGUE DAWLEY RAT; TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; ENDOTHELIAL PROGENITOR CELLS; FEMALE; GLOMERULONEPHRITIS, IGA; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84903857853     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-110     Document Type: Article

References (32)

1. Intercapillary deposits of IgA-IgG. Berger J, Hinglais N, J Urol Nephrol (Paris) 1968 74 9 694 695
2. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Choi YJ, Chakraborty S, Nguyen V, Nguyen C, Kim BK, Shim SI, Suki WN, Truong LD, Hum Pathol 2000 31 12 1491 1497 (Pubitemid 32049007)
3. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. Ohashi R, Kitamura H, Yamanaka N, J Am Soc Nephrol 2000 11 1 47 56 (Pubitemid 30020425)
4. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ, J Am Soc Nephrol 2001 12 7 1434 1447 (Pubitemid 32666326)
5. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ, J Am Soc Nephrol 2001 12 7 1448 1457 (Pubitemid 32666327)
6. Isolation of putative progenitor endothelial cells for angiogenesis. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM, Science 1997 275 5302 964 967 (Pubitemid 27087709)
7. Origin of endothelial progenitors in human postnatal bone marrow. Reyes M, Dudek A, Jahagirdar R, Koodie L, Marker PH, Verfaillie CM, J Clin Invest 2002 109 3 337 346 (Pubitemid 34141807)
8. Animal models of IgA nephropathy. Emancipator SN, Curr Protoc Immunol 2001 11 nit.15
9. Comparison of two rat models of IgA nephropathy. Peng W, Liu ZR, J South Med Univ 2008 28 10 1842 1845 in Chinese
10. The modification of laboratory IgA nephropathy model. Tang Y, Lou TQ, Cheng CL, J Zhongshan Univ (Med) 2006 27 2 184 187
11. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB, Arterioscler Thromb Vasc Biol 2004 24 2 288 293 (Pubitemid 38197580)
12. Autologous culture-modified mono- nuclear cells confer vascular protection after arterial injury. Gulati R, Jevremovic D, Peterson TE, Witt TA, Kleppe LS, Mueske CS, Lerman A, Vile RG, Simari RD, Circulation 2003 108 12 1520 1526 (Pubitemid 37176461)
13. An update on the pathogenesis and treatment of IgA nephropathy. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J, Kidney Int 2012 81 9 833 843
14. Current therapy for IgA nephropathy. Floege J, Eitner F, J Am Soc Nephrol 2011 22 10 1785 1794
15. Peripheral blood CD34 + KDR + endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Fadini GP, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A, de Kreutzenberg SV, Stroke 2006 37 9 2277 2282 (Pubitemid 44337169)
16. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Prunier F, Pfister O, Hadri L, Del Monte F, Liao R, Hajjar RJ, Am J Physiol Heart Circ Physiol 2007 292 1 522 529
17. Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke. Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, Carothers J, Stroke 2002 33 5 1362 1368 (Pubitemid 34517061)
18. Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Akita T, Murohara T, Ikeda H, Sasaki K, Shimada T, Egami K, Imaizumi T, Lab Invest 2003 83 1 65 73 (Pubitemid 36126051)
19. Behavioral changes in unilaterally 6-hydroxy-dopamine lesioned rats after transplantation of differentiated mouse embryonic stem cells without morphological integration. Baier PC, Schindehütte J, Thinyane K, Flügge G, Fuchs E, Mansouri A, Paulus W, Gruss P, Trenkwalder C, Stem Cells 2004 22 3 396 404 (Pubitemid 38736623)
20. Rat marrow-derived multipotent adult progenitor cells differentiate into skin epidermal cells in vivo. Ji KH, Xiong J, Fan LX, Hu KM, Liu HQ, J Dermatol 2009 36 7 403 409
21. Role of hypoxia in the pathogenesis of renal disease. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C, Kidney Int Suppl 2005 99 46 S51
22. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nangaku M, J Am Soc Nephrol 2006 17 1 17 25
23. Hypoxia-inducible factors in the kidney. Haase VH, Am J Physiol Renal Physiol 2006 291 2 271 281
24. Hypoxia protects human corneal endothelium from tertiary butyl hydroperoxide and paraquat-induced cell death in vitro. Cheng Q, Nguyen T, Song HX, Bonanno J, Exp Biol Med (Maywood) 2007 232 3 445 453 (Pubitemid 46334062)
25. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Connes P, Perrey S, Varray A, Préfaut C, Caillaud C, Pflugers Arch 2003 447 2 231 238 (Pubitemid 38177738)
26. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor- kappaB and activating protein-1. Viedt C, Dechend R, Fei J, Hänsch GM, Kreuzer J, Orth SR, J Am Soc Nephrol 2002 13 6 1534 1547 (Pubitemid 34579243)
27. Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease. Murali NS, Ackerman AW, Croatt AJ, Cheng J, Grande JP, Sutor SL, Bram RJ, Bren GD, Badley AD, Alam J, Nath KA, Am J Physiol Renal Physiol 2007 292 2 837 F844
28. MCP-1: chemoattractant with a role beyond immunity: a review. Yadav A, Saini V, Arora S, Clin Chim Acta 2010 411 21-22 1570 1579
29. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP, J Am Soc Nephrol 1996 7 6 906 913 (Pubitemid 27465985)
30. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. Ostendorf T, Kunter U, van Roeyen C, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J, J Am Soc Nephrol 2002 13 3 658 667 (Pubitemid 34183930)
31. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis. Pozzi A, Voziyan PA, Hudson BG, Zent R, Curr Pharm Des 2009 15 12 1318 1333
32. Role of matrix metalloproteinases in renal pathophysiologies. Catania JM, Chen G, Parrish AR, Am J Physiol Renal Physiol 2007 292 3 905 911